Why the study?
Does abciximab compared to tirofiban improve outcomes or reduce bleeding in STEMI patients undergoing PPCI with ticagrelor?
Does abciximab compared to tirofiban improve outcomes or reduce bleeding in STEMI patients undergoing PPCI with ticagrelor?
In STEMI patients undergoing PPCI with ticagrelor, abciximab and tirofiban offer similar 30-day efficacy, but tirofiban is associated with higher bleeding rates and platelet count drops.
Tirofiban associated with higher bleeding; leaves open randomized confirmation before preferring either GPI in ticagrelor-treated STEMI PPCI.
= .760). In STEMI patients undergoing PPCI with ticagrelor, abciximab and tirofiban had similar rates in the composite efficacy endpoint at 30 days. The 30-day bleeding rate was significantly higher in the tirofiban group. Tirofiban administration was an independent predictor of both bleeding and platelet count drop.
No takes yet. Share an insight, caveat, or question.
Revilla-Martí et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: